Resmed's Q4 Earnings on Deck: What's in Store for the Stock?
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth
ResMed Earnings Growth Seen Strong as Ventilator Issue Clouds FY27, UBS Says
Mizuho Maintains Outperform on ResMed, Lowers Price Target to $220
ResMed Inc (NYSE:RMD) Offers a Quality Dividend Built on Strong Profitability and Financial Health
Citigroup Downgrades ResMed (RMD)
Citigroup Downgrades ResMed to Neutral, Lowers Price Target to $235
Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care
Jefferies Maintains Hold on ResMed, Lowers Price Target to $225
ResMed (RMD) Sells MatrixCare To Refocus On Sleep And Respiratory Health
ResMed's Q4 2026 Earnings: What to Expect
ResMed Analyst Backs Portfolio Reset
Resmed sharpens sleep care focus with $490m software business sale
Resmed to sell MatrixCare for $490M to private equity firm
ResMed Inc (NYSE:RMD) Builds on a Quality Foundation with Strong Profitability and Cash Conversion
RBC Capital Maintains Outperform on ResMed, Lowers Price Target to $276
Wells Fargo Maintains Equal-Weight on ResMed, Lowers Price Target to $225
ResMed to sell software business MatrixCare for $490 million
Frazier Healthcare Partners Announces Definitive Agreement to Acquire MatrixCare
Resmed Announces Agreement to Sell MatrixCare Business
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
